Department of Medicine, Divisions of Medical Oncology and Geriatrics, University of Rochester Medical Center, Rochester, New York.
Department of Medical Oncology, Hartford HealthCare Cancer Institute, Hartford, Connecticut.
J Am Geriatr Soc. 2019 May;67(5):1012-1019. doi: 10.1111/jgs.15943.
Oncology care has become increasingly complex, with a dramatic increase in the number of available therapy options. Many newly developed medications have novel mechanisms of action and include targeted therapies and immunotherapy options. These agents typically have unique side effects that differ from more traditional cytotoxic chemotherapy regimens. Older adults represent the majority of patients with cancer and it is important for geriatricians and primary care providers for older adults to have a general understanding of newer agents and novel therapies, in order to aid in decision-making and supportive care strategies during oncology treatment. This review provides a case-based approach to discussing emerging therapeutic treatment options, including targeted therapies and immune-based therapies, in two common malignancies affecting older adults. Incorporation of available evidence of specific novel therapies in older adult populations is discussed. J Am Geriatr Soc 67:1012-1019, 2019.
肿瘤学治疗变得日益复杂,可用的治疗方法数量显著增加。许多新开发的药物具有新颖的作用机制,包括靶向治疗和免疫治疗选择。这些药物通常具有不同于更传统细胞毒性化疗方案的独特副作用。老年人占癌症患者的大多数,老年病医生和初级保健提供者了解新药物和新疗法对于帮助制定决策和支持肿瘤治疗期间的支持性护理策略非常重要。本综述采用基于病例的方法讨论了两种常见影响老年人的恶性肿瘤的新兴治疗选择,包括靶向治疗和免疫治疗。讨论了在老年人群中使用特定新型疗法的现有证据。J Am Geriatr Soc 67:1012-1019, 2019.